Idraparinux | 162610-17-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Idraparinux
• 英文别名: (2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxyoxane-2-carboxylic acid
• CAS: 162610-17-5
• 化学式: C₃₈H₆₄O₄₉S₇
• 分子量: 1529.4
• InChiKey: AJBMORBNKXNZSF-COSHMZDQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -9.6
• 重原子数：
  94
• 可旋转键数：
  35
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  735
• 氢给体数：
  9
• 氢受体数：
  49

文献信息

• Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label
  申请人：De Kort Martin

  公开号：US20100029582A1

  公开（公告）日：2010-02-04

  The present invention relates compounds of the formula: oligosaccharide-spacer-(GpIIb/IIIa antagonist), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-II mediated) anti-Xa activity per se; the spacer is a bond or an essentially pharmacologically inactive linking residue; the GpIIb/IIIa antagonist is a residue mimicking the RGD and/or K(QA)GD fragment of fibrinogen, comprising a carboxylate moiety and a basic moiety located within the residue at a distance of 10-20 Å from each other; or a pharmaceutically acceptable salt thereof or a prodrug or a solvate thereof; wherein the compound of formula I further comprises at least one covalent bond with a biotin label or an analogue thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases. The antithrombotic activity of the compound of this invention can be neutralized in case of emergency upon administration of avidin, streptavidin and analogues thereof having high biotin affinity.
• METHOD OF PURIFYING IDRAPARINUX SODIUM
  申请人：AMPHASTAR PHARMACEUTICALS INC.

  公开号：US20160096856A1

  公开（公告）日：2016-04-07

  A method for the purification of idraparinux sodium includes: passing a solution including a crude idraparinux sodium through a column including a sodium ion exchange resin to obtain a first mixture; passing a solution including the first mixture through a gel chromatogaphy column to obtain a second mixture; and precipitating a purified idraparinux sodium from a solution including the second mixture.
• US8183228B2
  申请人：——

  公开号：US8183228B2

  公开（公告）日：2012-05-22
• US9873712B2
  申请人：——

  公开号：US9873712B2

  公开（公告）日：2018-01-23